| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Forte Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.80 |
| 52 Week High | US$18.75 |
| 52 Week Low | US$6.05 |
| Beta | 1.43 |
| 11 Month Change | 0% |
| 3 Month Change | -42.62% |
| 1 Year Change | -32.34% |
| 33 Year Change | -87.64% |
| 5 Year Change | n/a |
| Change since IPO | -98.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 37T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -1.8% |
| 1Y | -32.3% | -14.9% | 13.2% |
Return vs Industry: 37T underperformed the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: 37T underperformed the German Market which returned 13.2% over the past year.
Price Volatility
| 37T volatility | |
|---|---|
| 37T Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 37T's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 37T's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Paul A. Wagner | www.fortebiorx.com |
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc. Fundamentals Summary
| 37T fundamental statistics | |
|---|---|
| Market cap | €5.63m |
| Earnings (TTM) | -€33.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 37T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 37T income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.76m |
| Earnings | -US$35.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 37T perform over the long term?
See historical performance and comparison